Education
About Us
Working with TipRanks
Follow Us
Adaptimmune Therapeutics (ADAPY)
OTHER OTC:ADAPY
Experimental: Letetresgene Autoleucel
Neoplasms
Phase II
Active Not Recruiting
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Nov 21, 2024
―
Cyclophosphamide, Fludarabine, Gsk3901961
Neoplasms
Phase I
Terminated
Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer
Sep 15, 2023
―
Cyclophosphamide, Fludarabine, Gsk3845097
Neoplasms
Phase I
Terminated
Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Jul 05, 2023
―
Afamitresgene Autoleucel
Synovial Sarcoma, Osteosarcoma, Malignant Peripheral Nerve Sheath Tumor (Mpnst), Neuroblastoma (Nbl)
Phase I/II
Recruiting
SPEARHEAD-3 Pediatric Study
Nov 07, 2022
―
Autologous Genetically Modified Adp-A2m4cd8 Cells, Autologous Genetically Modified Adp-A2m4cd8 Cells In Combination With Nivolumab
Ovarian Cancer
Phase II
Active Not Recruiting
ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
Oct 26, 2022
―
Cyclophosphamide, Fludarabine, Gsk3901961, Gsk3845097, Gsk4427296
Neoplasms
Phase I
Terminated
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
Aug 21, 2020
―
Afamitresgene Autoleucel (Previously Adp-A2m4)
Synovial Sarcoma, Myxoid Liposarcoma
Phase II
Active Not Recruiting
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Jul 09, 2019
―
Cyclophosphamide, Fludarabine, Letetresgene Autoleucel (Lete-Cel, Gsk3377794)
Neoplasms
Phase II
Active Not Recruiting
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
May 10, 2019
―
Autologous Genetically Modified Afpᶜ³³²t Cells
Hepatocellular Cancer, Afp Expressing Tumors
Phase I
Active Not Recruiting
AFPᶜ³³²T in Advanced HCC
Apr 25, 2017
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Adaptimmune Therapeutics (ADAPY) have in its pipeline
ADAPY is currently developing the following drugs: Experimental: Letetresgene Autoleucel, Cyclophosphamide, Fludarabine, Gsk3901961, Cyclophosphamide, Fludarabine, Gsk3845097. These drug candidates are in various stages of clinical development as the company works toward FDA approval.